The BMW M3 Just Got More Expensive for 2026
One of BMW's most iconic cars is about to get pricier. A
leaked pricing guide
for the 2026 BMW M3 shows a $1,700 increase across the board. That means the cheapest M3 is now $79,575, including the $1,175 destination charge.
As
BMW Blog
points out, the M3 is vastly more expensive than when it first debuted in 2020. Back then, the car started at $70,895 including destination. On average, the price has climbed $1,736 per year. Here's a chart showing the differences in price for each trim versus last year (with destination included):
Trim
2026 Price
2025 Price
M3
$79,575
$77,875
M3 Competition
$83,775
$82,075
M3 Competition xDrive
$88,875
$87,175
Trim-wise, the M3 remains unchanged from last year. The base car, available exclusively with a six-speed manual, is the only trim where three pedals are available. If you want an automatic, you'll have to upgrade to the Competition model. Doing so also gets you 30 more horsepower, for a total of 503. And if you want all-wheel drive, you'll have to drop an extra $5,100 for the Competition xDrive model.
While the base M3 starts at nearly $80,000, you'll likely be paying more, considering the numerous options available. The most expensive is the Carbon Package ($15,300 for the base car or $14,300 for Competition trims), which adds an Alcantara steering wheel, carbon interior trim, carbon-ceramic brakes, and carbon bucket seats. You can also add the steering wheel, the carbon-ceramics, or the seats as stand-alone options for $500, $8,500, and $4,500, respectively. In other words, the 2026 M3 can quickly become a six-figure car.
BMW declined to comment on the leaked pricing guide's authenticity or contents. The document says production for the 2026 BMW M3 starts in July, with prices already in effect for orders being placed now. With production of the current M3 set to end later in the decade, BMW may come up with a special edition or two to commemorate the manual transmission, as it's unlikely to return for the next-gen car.
In other words, if you want an M3 with a stick, get your order in sooner rather than later.
More on the M3
The 2025 BMW M3 Competition Is a German GT-R: Video Review
We Drove Three of the Best BMW M3s Ever. One Stood Out
Get the best news, reviews, columns, and more delivered straight to your inbox, daily.
back
Sign up
For more information, read our
Privacy Policy
and
Terms of Use
.
Share this Story
Facebook
X
LinkedIn
Flipboard
Reddit
WhatsApp
E-Mail
Got a tip for us? Email:
tips@motor1.com
Join the conversation
(
)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
2 Recession-Proof Stocks to Buy and Hold
Even amid an uncertain economic environment, reliable companies can be found. Zoetis helps people care for pets, which many consider as honorary family members. HCA Healthcare offers services in high demand, regardless of economic conditions. 10 stocks we like better than Zoetis › President Trump's trade policies are sparking concerns about a potential recession. Though it's hard to predict an upcoming economic downturn, it's never a bad idea for investors to buy shares of companies that can perform relatively well even in bad times. These corporations often have robust underlying businesses built to deliver consistent results and superior returns over the long run. Here are two great examples for investors to consider: Zoetis (NYSE: ZTS) and HCA Healthcare (NYSE: HCA). Zoetis, a leading animal health company, has faced some challenges over the past year. The company's recent financial results weren't great, and it is dealing with increased competition for some of its growth drivers, including Apoquel, a medicine to treat allergic itch in dogs. However, as Zoetis points out, there is significant whitespace in this niche. It estimates that 13 million dogs are eligible for the medicine but aren't on any prescription, and another 7 million are undertreated. The company currently treats 12 million dogs with Apoquel and Cytopoint, a similar medicine. Although Zoetis markets products for livestock, poultry, and other animals, the company's work with pets, particularly cats and dogs, is one of the primary reasons it can survive a recession relatively unscathed. People view their pets as family members and are more than willing to pay a significant amount to ensure they are well cared for. The increased humanization of pets should also be a significant long-term growth driver for Zoetis, a trend that is particularly prevalent among younger generations, who are less likely to have children than older ones. It might be pushing it to say that pets are the new kids, but it's not too far from the truth for many pet owners. The rest of Zoetis' business grants it significant diversity. The animal health leader generally grows its revenue at rates faster than the industry average, something it has been able to do for a while, despite competition, through the continuous development of newer medicines. Two of its more recent important approvals, Solensia and Librela that treat osteoarthritis pain in cats and dogs, respectively, are becoming key growth drivers, too. So, despite being slightly in the red over the trailing-12-month period, Zoetis is well-equipped to handle a recession if one is coming, while delivering strong returns in the long run. Lastly, the stock is also an excellent pick for income seekers despite its unimpressive forward yield of 1.2%. Zoetis has increased its payouts by 502% in the past decade. Whether it's for dividends or growth, the healthcare specialist is a great option. HCA Healthcare's business remains in high demand even in recessions. The company is a leading hospital chain in the U.S., and even during economic downturns, people still require critical medical care. True, some procedures performed in the company's facilities are optional. Even for those that aren't, patients may sometimes postpone them when things get tough. So, there will be an impact on the company's results, but it should be fairly minimal. Over the past year, the company has faced another source of headwinds. Various natural disasters, including hurricanes, impacted its financial results in some areas, resulting in lower revenue than anticipated. Still, HCA Healthcare continues to deliver decent updates. In the first quarter, the company's revenue increased by a modest 5.7% year over year to $18.3 billion. Its earnings per share came in at $6.45, up 8.8% compared to the year-ago period. Despite this headwind, HCA Healthcare's long-term prospects are attractive. An aging population that will require more medical care should lead to increased spending on precisely the kinds of services it offers. HCA Healthcare has also deepened its relationships with physicians, patients, and third-party payers over time, partly through the adoption of more services. It would be challenging for any newcomer to seriously challenge HCA Healthcare, considering the ecosystem it has already built, which arguably grants it a network effect. Although there is competition, HCA Healthcare has generally increased its market share over the past decade. The stock should continue delivering superior returns long after the next recession hits, whenever that happens. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Zoetis. The Motley Fool recommends HCA Healthcare. The Motley Fool has a disclosure policy. 2 Recession-Proof Stocks to Buy and Hold was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
ECB cuts interest rates to 2% in effort to boost flagging eurozone growth
The European Central Bank has cut interest rates to 2% in an effort to boost flagging economic growth across the eurozone. The ECB, making its eighth quarter-point cut in a year, said the 20-member currency bloc needed a cut in the cost of borrowing as it reeled from the damage caused by Donald Trump's trade wars. Economic growth has slowed across the eurozone and especially in France, Germany and Italy, while the outlook for next year is weak, according to forecasts by the EU. The move cuts the cost of borrowing to less than half the level in the UK, where the Bank of England last month cut interest rates to 4.25%, and the level set in the US by the Federal Reserve of between 4.25% and 4.5%. The US president has railed against the Fed's chair, Jerome Powell, and what he describes as the Fed's policy of maintaining high interest rates. Related: UK interest rates more uncertain due to Trump policies, says Bank governor On Tuesday, Trump noted the repeated interest rate cuts in Europe, and said: 'ADP NUMBER OUT!!! 'Too Late' Powell must now LOWER THE RATE. He is unbelievable!!!' in a reference to weak private sector payroll numbers given by the US data provider Automatic Data Processing. The ECB cut its main deposit rate from 2.25% to 2% after inflation across the eurozone fell to 1.9% last month, below the central bank's 2% target for the first time since last September. The ECB said that US tariffs would hit growth, but extra government spending on defence would fill some of the gap. 'While the uncertainty surrounding trade policies is expected to weigh on business investment and exports, especially in the short term, rising government investment in defence and infrastructure will increasingly support growth over the medium term,' it said. The role of the ECB president, Christine Lagarde, has come under the spotlight since the ousted head of the World Economic Forum, Klaus Schwab, said she had been involved in discussions to replace him. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
LED Lighting, EV Charging Station and Electrical Maintenance Solutions Provider Orion Hosts Q4 Conference Call Thursday, June 26th at 10am ET
MANITOWOC, Wis., June 05, 2025 (GLOBE NEWSWIRE) -- Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electrical vehicle charging station, and maintenance services solutions, will host a conference call and webcast to review its fourth quarter and fiscal 2025 results on Thursday, June 26, 2025 at 10:00 a.m. ET. Orion will release results prior to the market's opening that day. Webcast and Call Details Date / Time: Thursday, June 26th at 10:00 a.m. ET Live Call Registration: call participants must pre-register using the URL above to receive the dial-in information. You may re-register if you lose the dial-in or PIN #. Webcast & Replay: About Orion Energy Systems (at provides energy efficient LED lighting and controls, electrical vehicle (EV) charging solutions, and electrical maintenance services. Orion specializes in turnkey design-through-installation solutions for large national customers as well as projects through ESCO and distribution partners. Orion is committed to helping customers achieve their business, financial and environmental goals with high quality, innovative and safe solutions delivered with high levels of customer service and reliability. Orion is committed to operating responsibly throughout all areas of our organization. Learn more about our Sustainability and Governance priorities, goals and progress here or visit our website at Engage with UsX: @OrionLighting and @OrionLightingIRStockTwits: @OESX_IR Investor Relations Contacts Per Brodin, CFO William Jones; David Collins Orion Energy Systems, Inc. Catalyst IR pbrodin@ (212) 924-9800 or OESX@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
